Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 12, 2008, Pages 4351-4355

  Cirioni, Oscar ^a,f   Ghiselli, Roberto ^a   Silvestri, Carmela ^a   Kamysz, Wojciech ^b   Orlando, Fiorenza ^c   Riva, Alessandra ^a   Kamysz, Elzbieta ^d   Castelletti, Sefora ^a   Rocchi, Marco ^e   Saba, Vittorio ^a   Scalise, Giorgio ^a   Giacometti, Andrea ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c INRCA   (Italy)

^d UNIVERSITY OF GDA SK   (Poland)

^e UNIVERSITY OF URBINO   (Italy)

^f C/o Ospedale Regionale ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CLARITHROMYCIN; ENDOTOXIN; POLYPEPTIDE ANTIBIOTIC AGENT; TACHYPLESIN 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; ESCHERICHIA COLI; LETHALITY; MALE; NONHUMAN; PERITONEUM; PERITONITIS; PRIORITY JOURNAL; RAT; SEPSIS; WISTAR RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CLARITHROMYCIN; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DRUG THERAPY, COMBINATION; ENDOTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; MALE; PEPTIDES, CYCLIC; RATS; RATS, WISTAR; SEPSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 57049148686     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00086-08     Document Type: Article

References (33)

1. Alberti, C., C. Brun-Buisson, H. Burchardi, C. Martin, S. Goodman, A. Artigas, A. Sicignano, M. Palazzo, R. Moreno, R. Boulmé, E. Lepage, and R. Le Gall. 2002. Epidemiology of sepsis and infection in ICU patients from an international multicenter cohort study. Intensive Care Med. 28:108-121.
2. Balakrishna, R., S. J. Wood, T. B. Nguyen, K. A. Miller, E.V. Suresh Kumar, A. Datta, and S. A. David. 2006. Structural correlates of antibacterial and membrane-permeabilizing activities in acylpolyamines. Antimicrob. Agents Chemother. 50:852-861.
3. Blondeau, J. M., E. Decarolis, K. L. Metzler, and G. T. Hansen. 2002. The macrolides. Expert Opin. Investig. Drugs 11:189-215.
4. Christensen, T. 1979. Qualitative test for monitoring coupling completeness in solid phase peptide synthesis using chloranil. Acta Chem. Scand. Series B 33:763-766.
5. Cirioni, O., A. Giacometti, R. Ghiselli, C. Bergnach, F. Orlando, C. Silvestri, F. Mocchegiani, A. Licci, B. Skerlavaj, V. Saba, M. Rocchi, M. Zanetti, and G. Scalise. 2006. LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. Antimicrob. Agents Chemother. 50:1672-1679.
6. Cirioni, O., A. Giacometti, R. Ghiselli, W. Kamysz, F. Orlando, F. Mocchegiani, C. Silvestri, A. Licci, L. Chiodi, J. Łukasiak, G. Scalise, and V. Saba. 2006. Citropin 1.1-treated central venous catheters improve the efficacy of hydrophobic antibiotics in the treatment of experimental staphylococcal catheter-related infection. Peptides 27:1210-1216.
7. Diekema, D. J., M. A. Pfaller, R. N. Jones, G. V. Doern, P. L. Winokur, A. C. Gales, H. S. Sader, K. Kugler, and M. Beach. 1999. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin. Infect. Dis. 29:595-607.
8. Eliopoulos, G. M., and R. C. Moellering, Jr. 1996. Antimicrobial combinations, p. 330-393. In V. Lorian (ed.), Antibiotics in laboratory medicine. Williams & Wilkins, Baltimore, MD.
9. Fields, G. B., and R. L. Noble. 1990. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 35:161-214.
10. Giacometti, A., O. Cirioni, R. Ghiselli, F. Mocchegiani, C. Silvestri, F. Orlando, W. Kamysz, J. Łukasiak, V. Saba, and G. Scalise. 2006. Amphibian peptides prevent endotoxemia and bacterial translocation in bile duct-ligated rats. Crit. Care Med. 34:2415-2420.
11. Giamarellos-Bourboulis, E. J. 2008. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int. J. Antimicrob. Agents 31:12-20.
12. Giamarellos-Bourboulis, E. J., T. Adamis, G. Laoutaris, L. Sabracos, V. Koussoulas, M. Mouktaroudi, D. Perrea, P. E. Karayannacos, and H. Giamarellou. 2004. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 48:93-99.
13. Gough, M., R. E. W. Hancock, and N. M. Kelly. 1996. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect. Immun. 64:4922-4927.
14. Hancock, R. E. W. 2001. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis. 1:156-164.
15. Hancock, R. E., and H. G. Sahl. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24:1551-1557.
16. Hirakura, Y., S. Kobayashi, and K. Matsuzaki. 2002. Specific interactions of the antimicrobial peptide cyclic β-sheet tachyplesin I with lipopolysaccharides. Biochim. Biophys. Acta 1562:32-36.
17. Imura, Y., M. Nishida, Y. Ogawa, Y. Takakura, and K. Matsuzaki. 2007. Action mechanism of tachyplesin I and effects of PEGylation. Biochim. Biophys. Acta 1768:1160-1169.
18. Junkes, C., A. Wessolowski, S. Farnaud, R. W. Evans, L. Good, M. Bienert, and M. Dathe. 6 November 2007. The interaction of arginine- and tryptophan-rich cyclic hexapeptides with Escherichia coli membranes. J. Pept. Sci. [Epub ahead of print.] doi:10.1002/psc.940.
19. Matsuzaki, K., S. Yoneyama, N. Fujii, K. Miyajima, K. Yamada, Y. Kirino, and K. Anzai. 1997. Membrane permeabilization mechanisms of a cyclic antimicrobial peptide, tachyplesin I, and its linear analog. Biochemistry 36:9799-9806.
20. McCafferty, D. G., P. Cudic, M. K. Yu, D. C. Behenna, and R. Kruger. 1999. Synergy and duality in peptide antibiotic mechanisms. Curr. Opin. Chem. Biol. 3:672-680.
21. Meng, G., M. Rutz, M. Schiemann, J. Metzger, A. Grabiec, R. Schwandner, P. B. Luppa, F. Ebel, D. H. Busch, S. Bauer, H. Wagner, and C. J. Kirscning. 2004. Antagonist antibody prevents toll-like receptor 2-driven lethal shocklike syndromes. J. Clin. Investig. 113:1473-1481.
22. Munford, R. S. 2006. Severe sepsis and septic shock: the role of gramnegative bacteremia. Annu. Rev. Pathol. 1:467-496.
23. Nakamura, T., H. Furunaka, T. Miyata, F. Tokunaga, T. Muta, S. Iwanaga, M. Niwa, T. Takao, and Y. Shimonishi. 1988. Tachyplesin, a class of antimicrobial peptide from the hemocytes of the horseshoe crab (Tachypleus tridentatus): isolation and chemical structure. J. Biol. Chem. 263:16709-16713.
24. NCCLS. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. NCCLS, Wayne, PA.
25. Ofek, I., S. Cohen, R. Rahmani, K. Kabha, Y. Herzig, and E. Rubinstein. 1994. Antibacterial synergism of polymyxin B nonapeptide and hydrophobic antibiotics in experimental gram-negative infections in mice. Antimicrob. Agents Chemother. 38:374-377.
26. Papo, N., and Y. Shai. 2003. Can we predict biological activity of antimicrobial peptides from their interactions with model phospholipids membranes? Peptides 24:1693-1703.
27. Radek, K., and R. Gallo. 2007. Antimicrobial peptides: natural effectors of the innate immune system. Semin. Immunopathol. 29:27-43.
28. Schuldiner, S. 2006. Structural biology: the ins and outs of drug transport. Nature 443:156-157.
29. Tenover, F. C. 2006. Mechanisms of antimicrobial resistance in bacteria. Am. J. Infect. Control 34:S3-S10.
30. Tsubery, H., H. Yaakov, S. Cohen, T. Giterman, A. Matityahou, M. Fridkin, and I. Ofek. 2005. Neopeptide antibiotics that function as opsonins and membrane-permeabilizing agents for gram-negative bacteria. Antimicrob. Agents Chemother. 49:3122-3128.
31. Vaara, M. 1993. Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria. Antimicrob. Agents Chemother. 37:354-356.
32. Vaara, M., and M. Nurminen. 1999. Outer membrane permeability barrier in Escherichia coli mutants that are defective in the late acyltransferases of lipid A biosynthesis. Antimicrob. Agents Chemother. 43:1459-1462.
33. Vaara, M., and M. Porro. 1996. Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric bacteria. Antimicrob. Agents Chemother. 40:1801-1805.